Skip to main content
SpringerLink
Log in

Aflibercept, ranibizumab are not cost effective in DME

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ross EL et al. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment. Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmology : 9 Jun 2016. Available from: URL: http://dx.doi.org/10.1001/jamaophthalmol.2016.1669

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aflibercept, ranibizumab are not cost effective in DME. PharmacoEcon Outcomes News 756, 10 (2016). https://doi.org/10.1007/s40274-016-3159-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3159-1

Search

Navigation